DK1601352T3 - Kombineret anvendelse af et fibrat og orlistat til behandling af fedme - Google Patents

Kombineret anvendelse af et fibrat og orlistat til behandling af fedme

Info

Publication number
DK1601352T3
DK1601352T3 DK04720007T DK04720007T DK1601352T3 DK 1601352 T3 DK1601352 T3 DK 1601352T3 DK 04720007 T DK04720007 T DK 04720007T DK 04720007 T DK04720007 T DK 04720007T DK 1601352 T3 DK1601352 T3 DK 1601352T3
Authority
DK
Denmark
Prior art keywords
fibrate
orlistat
combined use
treat obesity
obesity
Prior art date
Application number
DK04720007T
Other languages
English (en)
Inventor
Alan Edgar
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of DK1601352T3 publication Critical patent/DK1601352T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
DK04720007T 2003-03-13 2004-03-12 Kombineret anvendelse af et fibrat og orlistat til behandling af fedme DK1601352T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (en) 2003-03-13 2003-03-13 Combined use of a fibrate and orlistat for the treatment of obesity
PCT/EP2004/004010 WO2004080450A2 (en) 2003-03-13 2004-03-12 Combined use of a fibrate and orlistat for the treatment of obesity

Publications (1)

Publication Number Publication Date
DK1601352T3 true DK1601352T3 (da) 2008-05-13

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04720007T DK1601352T3 (da) 2003-03-13 2004-03-12 Kombineret anvendelse af et fibrat og orlistat til behandling af fedme

Country Status (18)

Country Link
US (1) US20070078179A1 (da)
EP (2) EP1457206A1 (da)
JP (1) JP4928256B2 (da)
CN (1) CN100562313C (da)
AT (1) ATE384520T1 (da)
AU (1) AU2004218938B2 (da)
BR (1) BRPI0408322A (da)
CA (1) CA2518205C (da)
DE (1) DE602004011486T2 (da)
DK (1) DK1601352T3 (da)
EA (1) EA009127B1 (da)
ES (1) ES2300750T3 (da)
IL (1) IL170519A (da)
MX (1) MXPA05009718A (da)
NO (1) NO20054700L (da)
PT (1) PT1601352E (da)
WO (1) WO2004080450A2 (da)
ZA (1) ZA200507227B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2190303A1 (en) * 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
MX336980B (es) 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
CN104870018A (zh) * 2012-12-21 2015-08-26 默克专利股份有限公司 具有改善的活性物质的释放作为药物制剂中载体的碱式碳酸镁

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
WO2001060807A1 (en) * 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
PT1601352E (pt) 2008-04-07
IL170519A (en) 2010-12-30
JP4928256B2 (ja) 2012-05-09
CA2518205A1 (en) 2004-09-23
HK1083767A1 (en) 2006-07-14
MXPA05009718A (es) 2005-10-18
CA2518205C (en) 2012-05-08
ZA200507227B (en) 2006-11-29
EP1601352B1 (en) 2008-01-23
AU2004218938A1 (en) 2004-09-23
CN1826108A (zh) 2006-08-30
CN100562313C (zh) 2009-11-25
EA009127B1 (ru) 2007-10-26
ATE384520T1 (de) 2008-02-15
WO2004080450A3 (en) 2005-02-24
EA200501259A1 (ru) 2006-02-24
US20070078179A1 (en) 2007-04-05
EP1601352A2 (en) 2005-12-07
AU2004218938B2 (en) 2009-04-09
EP1457206A1 (en) 2004-09-15
JP2006520365A (ja) 2006-09-07
BRPI0408322A (pt) 2006-03-14
ES2300750T3 (es) 2008-06-16
IL170519A0 (en) 2006-10-05
DE602004011486D1 (de) 2008-03-13
WO2004080450A2 (en) 2004-09-23
DE602004011486T2 (de) 2009-01-15
NO20054700L (no) 2005-10-12

Similar Documents

Publication Publication Date Title
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
DK1660057T3 (da) Kombinationsterapi til behandling af neovaskulære øjenlidelser
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
NO20034056D0 (no) Proliferative sykdommer
ATE461217T1 (de) Glp-1-verbindungen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
DK1545548T3 (da) Anvendelsen af kombinationen af ciclesonid og antihistaminer til behandingen af allergisk rhinitis
DK1686997T3 (da) Inhibitorer af mutantformen af KIT
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
DK1569634T3 (da) Anvendelse af en PPAR-agonist og metformin til behandling af fedme
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
NO20055450D0 (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
DK1400522T3 (da) Forbindelser til behandling af impotens
DE602004011679D1 (de) Behandelung von Störungen
IS8138A (is) Gaboxadól til meðhöndlunar á þunglyndi og öðrum geðrænum truflunum
DK1569650T3 (da) Anvendelse af levocetirizin til behandling af vedvarende rhinitis allergica
FIU20010133U0 (fi) Jäteveden käsittelylaitteisto
IS8496A (is) Samsetningar til meðhöndlunar á fjölgunarsjúkdómum
ITLE20020023A1 (it) Trattamento gas